News Grail's multi-cancer test fluffs its lines in UK trial Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.
News AstraZeneca raises guidance on stellar cancer drugs growth AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.
News Takeda signs $1.7bn AI alliance with Iambic Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.
News Lilly strikes $8.8bn-plus alliance with China's Innovent Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.
News Flagship's AI-focused Generate Biomedicines files IPO Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.
News Grail multi-cancer test taps into Hims & Hers network Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.